Investor Presentaiton

Strong track record Unique model Large moat Significant opportunity Compounding growth Expect faster growth than S&P 500, healthcare & biopharma Top-line growth comparison 2020-2025e (1) 8% S&P 500(1) revenue (~1.5x) 11-14% 9% ~1.5x 11-14% 5% >2x ROYALTY PHARMA Healthcare (1,3) ROYALTY PHARMA Biopharma group (1,4) ACR guidance (2) revenue ACR guidance (2) revenue 11-14% ROYALTY PHARMA ACR guidance (2) Longer term, we expect to achieve ACR CAGR of 10% or more over this decade 1. Based on median growth rates for consensus sales. ROYALTY PHARMA 2. See slide 114 for definitions. Refer to the appendix for a GAAP to non-GAAP reconciliation. 3. Healthcare industry sector of S&P 500 constituents. 4. Biopharma group include AbbVie, Lilly, Bristol-Myers Squibb, Pfizer, Johnson & Johnson, Merck & Co., Regeneron, Vertex, Biogen, Gilead, Amgen, Roche, Novartis, GSK, Sanofi, Novo Nordisk and AstraZeneca. 23

View entire presentation